BioCardia announced that Japan's Pharmaceutical and Medical Device Agency (PMDA) has positively reviewed the clinical safety and efficacy data of its CardiAMP Cell Therapy for ischemic heart failure, deeming it likely sufficient for market clearance. The PMDA agreed on the acceptability of U.S.-developed clinical data and the therapy's use in patients, with plans for post-marketing studies in Japan. BioCardia awaits detailed feedback and a potential filing timeline, aiming to introduce the first minimally invasive biologic therapy for ischemic heart failure in Japan. This marks a significant step toward regulatory approval and market entry in Japan for CardiAMP, which uses a patient's own bone marrow cells to treat heart failure.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
